Renexxion And Dr. Falk Expand Naronapride Study, Dose First US Patient
13 Aug 2024 //
GLOBENEWSWIRE
Renexxion Announce FDA Clearance of the Naronapride to Treat Gastroparesis
27 Mar 2024 //
GLOBENEWSWIRE
Renexxion to Present at the Oppenheimer 34áµ—Ê° Annual Healthcare Conference
01 Feb 2024 //
GLOBENEWSWIRE
Renexxion Ireland Announces FDA Clearance of IND)Application for Naronapride
24 Jan 2024 //
GLOBENEWSWIRE
Renexxion has Completed Consultation with FDA for Development of Naronapride
20 Dec 2023 //
GLOBENEWSWIRE
Renexxion Announces Issuance of Two U.S. Patents Covering Naronapride
30 Nov 2023 //
GLOBENEWSWIRE
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
04 Oct 2023 //
GLOBENEWSWIRE
Renexxion Ireland begins Phase IIb trial of gastroparesis therapy
16 Feb 2023 //
CLINICAL TRIALS ARENA
Renexxion reveals plans to address GI symptoms in cystic fibrosis patients
24 Jan 2023 //
CLINICAL TRIALS ARENA
Renexxion Announces Opening of IND Application for Naronapride
10 Jan 2023 //
PR NEWSWIRE
Renexxion Ireland Announces Issuance of New US Patent covering Naronapride
23 Dec 2021 //
PRNEWSWIRE
Renexxion Ireland Announces Issuance of New US Patent covering Naronapride
23 Dec 2021 //
PRNEWSWIRE